Investors & Media

Events & Presentations

  • Type:
  • Year:
  • Sep. 9 - 13, 2017   //  Milan, Italy

    Kamada to participate in ERS International Congress 2017

    This association organise a range of scientific and educational events including the ERS International Congress, the largest conference in the respiratory field. Other events include courses, research seminars, the Lung Science Conference and, Sleep and Breathing conference.

  • Sep. 5 - 6, 2017   //  Shanghai, China

    Kamada to participate in 6th Annual Bioplasma Asia 2017

    Over the past 5 years, Bioplasma World Asia has established itself as Asia’s definitive meeting place for plasma fractionators, investors, regulators and technology providers. With the mission to propel Asia towards self-sufficiency, it has brought together over 400 opinion leaders from Asia and globally from 2012 to 2015, and helped hundreds of plasma and blood products industry players to address pressing issues, share best practices and form partnerships.

  • Aug. 30 - 31, 2017   //  Wolfsberg, Switzerland

    Kamada to participate in the meeting of the Partners for Rabies Prevention (PRP)

    Annual meeting of the informal group Partners for Rabies Prevention (PRP). The PRP is an group of key representatives for rabies within the World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), rabies vaccine manufacturing companies, academics, implementers, and Non-Governmental Organizations sat together informally, with each having a voice in discussions on how to tackle the neglect of rabies with practical ways forward.

  • Aug. 1, 2017   //  Conference Call

    Kamada to Host Second Quarter 2017 Financial Results Conference Call on August 1

    Direct webcast link: http://public.viavid.com/index.php?id=125164

    Rehovot, Israel – July 27, 2017 — Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the second quarter ended June 30, 2017 prior to the open of the U.S. financial markets on Tuesday, August 1.

    Kamada management will host an investment community conference call on Tuesday, August 1 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-221-9591 (from within the U.S.), 1 80 924 6042 (from Israel), or 719-325-4893 (International) and entering the conference identification number: 2753969. The call will also be webcast live on the Internet on the Company’s website at www.kamada.com.

    A replay of the call will be accessible two hours after its completion through August 15 by dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.) and entering the conference identification number: 2753969. The call will also be archived for 90 days on the Company’s website at www.kamada.com.

    About Kamada
    Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors. In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trial in Europe. Kamada has also completed its Phase 2 clinical trial in the U.S. for the treatment of AAT deficiency using our proprietary inhaled AAT. In addition, Kamada’s intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 pharmaceutical products in Israel that are manufactured by third parties.

    Cautionary Note Regarding Forward-Looking Statements
    This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or other markets in which Kamada operates or intends to operate, or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    CONTACTS:
    Gil Efron
    Deputy CEO & Chief Financial Officer
    IR@kamada.com
    Bob Yedid
    LifeSci Advisors, LLC
    646-597-6989
    Bob@LifeSciAdvisors.com

  • Jun. 19 - 22, 2017   //  San Diego, Ca, USA

    Kamada to participate in BIO International Convention, San Diego USA

    The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

  • Jun. 9 - 13, 2017   //  San Diego, California

    Kamada to participate in ADA (American Diabetes Association) 77th Scientific Sessions

    This program offers a unique opportunity for early career endocrinologists who treat diabetes and its complications to take advantage of small-group learning and networking experiences such as:

    * Peer-to-peer engagement during small-group breakout sessions June 8-9.

    * Opportunities to meet senior scientists/clinicians during receptions and “Lunch with the Expert” sessions.

    * Support in navigating the primary meeting, the 77th Scientific Sessions with ongoing activities and a private lounge.

  • Jun. 6 - 9, 2017   //  New York, NY

    Kamada to participate in Jefferies 2017 Global Healthcare Conference

    The Jefferies 2017 Global Healthcare conference will feature an extensive range of public & private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.

  • May. 24 - 26, 2016   //  Tel Aviv, Israel

    IATI Biomed 2016

    This year, as we mark our 15th anniversary, we are excited to introduce a new format in which we will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life sciences.

  • May. 13 - 18, 2016   //  San Francisco, California

    ATS- International Conference 2016

    The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

  • May. 9, 2016   //  Conference call

    First Quarter Financial Results Conference Call

    Link to webcast

    Kamada management will host an investment community conference call on Monday, May 9, 2016 at 8:30 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-803-5993 (from within the U.S.), 706-634-5454 (from outside the U.S.) and entering the conference identification number: 5573974. The call will also be webcast live on the internet on the Company’s website at www.kamada.com.

    A replay of the call will be accessible two hours after its completion through May 15, 2016 by dialing 855-859-2056 (from within the U.S.) or 404-537-3406 (from outside the U.S.) and entering the conference identification number: 5573974. The call will also be archived for 90 days on the Company’s website at www.kamada.com.